Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. orthocat

ORTHOCAT SIGNED

Bioorthogonal Photocatalytic Activation of Metal-Based Prodrugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ORTHOCAT project word cloud

Explore the words cloud of the ORTHOCAT project. It provides you a very rough idea of what is the project "ORTHOCAT" about.

surgery    strategy    wellbeing    activation    agents    cancer    anticancer    dna    outcome    death    cell    dual    complexes    vectors    activating    original    unconventional    compounds    prodrugs    photocatalytic    hypoxic    therapeutic    cells    limits    oxygen    redox    synergistically    clinics    selectivity    mitochondria    riboflavin    generate    nanoplatforms    transition    accomplishes    triphenylphosphonium    involve    mechanism    simultaneously    framework    prodrug    inside    catalytic    tumour    pt    tumours    new    multidisciplinary    4619    therapy    patient    singlet    accumulate    sci    mission    efficiency    trigger    care    kill    photochemistry    metal    light    photocatalyst    pdt    strategies    efficacy    drugs    innovative    proposes    species    photodynamic    effectiveness    combines    depends    fewer    selectively    photoactivatable    potentially    cellular    chem    photochemotherapy    nevertheless    background    employing    imbalance    delicate    successful    vast    intimately    reducing    class    organelle    solid    orthocat    2017    act    mitochondrial    homeostasis    photosensitizer    action    designing    convenient    once   

Project "ORTHOCAT" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER 

Organization address
address: PASEO MANUEL LARDIZABAL 4
city: DONOSTIA SAN SEBASTIAN
postcode: 20018
website: http://dipc.ehu.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-10   to  2020-09-09

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER ES (DONOSTIA SAN SEBASTIAN) coordinator 158˙121.00

Map

 Project objective

New cancer care methodologies with fewer side effects and no need for major surgery are required to enhance patient wellbeing. Photodynamic Therapy (PDT) partially accomplishes such mission employing light and a photosensitizer. Nevertheless, the PDT mechanism of action intimately depends on oxygen, which limits its efficacy, particularly in hypoxic solid tumours. Promising strategies to improve the impact of PDT in the clinics currently involve the design of photoactivatable transition metal complexes, a class of compounds which combines the rich photochemistry of metal complexes with the vast background of metal-based drugs in cancer therapy.

In this framework, ORTHOCAT proposes an original and multidisciplinary strategy to exploit the efficiency and selectivity of riboflavin as unconventional photocatalyst for the activation of Pt(IV) anticancer prodrugs (Chem. Sci. 2017, 8, 4619).

The project aims at designing novel riboflavin-based catalytic systems capable of activating Pt(IV) anticancer prodrugs inside the mitochondria of tumour cells. In particular, I will use triphenylphosphonium targeting vectors to develop new photocatalytic prodrug systems and delivery nanoplatforms which selectively accumulate in the mitochondria. Once in the organelle, riboflavin will act as singlet oxygen photosensitizer for PDT and simultaneously as photocatalyst to generate Pt(II) species for targeting mitochondrial DNA (photochemotherapy). Imbalance of mitochondrial delicate redox homeostasis by ORTHOCAT dual agents can trigger cell death through convenient cellular pathways. Therefore, ORTHOCAT prodrug systems will synergistically kill cancer cells with increased effectiveness, while potentially reducing side effects of metal-based drugs. Successful outcome of the project has the potential to deliver innovative therapeutic agents for cancer photochemotherapy.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-08-05 15:14:49

Take a look to the deliverables list in detail:  detailed list of ORTHOCAT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORTHOCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORTHOCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More  

DEF2DEV (2019)

Identification of the mode of action of plant defensins during root development and plant defense responses.

Read More